RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Newron Pharmaceuticals SpA Stock

Newron Pharmaceuticals SpA Debt 2025

Newron Pharmaceuticals SpA Debt

42.08 EUR

Ticker

NWRN.SW

ISIN

IT0004147952

WKN

A0LF18

In 2025, Newron Pharmaceuticals SpA's total debt was 42.08 EUR, a 30.52% change from the 32.24 EUR total debt recorded in the previous year.

Newron Pharmaceuticals SpA Aktienanalyse

What does Newron Pharmaceuticals SpA do?

Newron Pharmaceuticals SpA is an international biopharmaceutical company specializing in the development of novel products for the treatment of central nervous system (CNS) disorders. The company is headquartered in Italy and is listed on the SIX Swiss Exchange. The history of Newron Pharmaceuticals SpA dates back to 1996 when it was founded by a team of experienced pharmaceutical experts. Since then, the company has become a leading player in the development of therapies for rare neurological disorders. The focus is particularly on diseases such as Parkinson's and Rett syndrome, as well as other neurological disorders. Newron Pharmaceuticals SpA's business model is based on the research and development of novel drugs in the field of the central nervous system. The company typically conducts research and development in its own laboratories and collaborates closely with external experts and institutions to develop innovative therapies. The goal is to develop patient-oriented, innovative drugs and successfully bring them to market. The company has several product candidates in various stages of development, including Xadago® (Safinamide), an approved drug for the treatment of Parkinson's. Similarly, an orally administered drug is being tested in phase III of clinical development with the aim of improving motor symptoms in Parkinson's. Another important product candidate of Newron Pharmaceuticals SpA is Sarizotan, an innovative drug for the treatment of Rett syndrome, a rare neurological disease that primarily affects girls. The company has entered into a partnership with the American company Rett Syndrome Research Trust (RSRT) to promote further development of the drug. In addition to researching and developing new drugs, Newron also actively works on advancing existing treatment approaches. For example, collaborations with academic institutions are used to incorporate new knowledge from the fields of molecular biology and genetics to further expand existing therapeutic approaches. The company follows an integrative approach, focusing on collaboration between research and development teams, clinical experts, patient organizations, and regulatory authorities. The goal is to treat patients with novel and effective therapies. Overall, Newron Pharmaceuticals SpA is an internationally operating biopharmaceutical company dedicated to researching and developing novel therapies in the field of the central nervous system. Through its innovative research and development activities and close collaboration with experts, institutions, and patient organizations, the company significantly contributes to the advancement of treatment options for neurological disorders. Newron Pharmaceuticals SpA ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding Newron Pharmaceuticals SpA's Debt Structure

Newron Pharmaceuticals SpA's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Newron Pharmaceuticals SpA's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Newron Pharmaceuticals SpA’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Newron Pharmaceuticals SpA’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Newron Pharmaceuticals SpA stock

What is the debt of Newron Pharmaceuticals SpA this year?

Newron Pharmaceuticals SpA has a debt level of 42.08 EUR this year.

What was the debt of Newron Pharmaceuticals SpA compared to the previous year?

The debt of Newron Pharmaceuticals SpA has increased by 30.52% compared to the previous year increased.

What are the consequences of high debt for investors in Newron Pharmaceuticals SpA?

High debt can pose a risk for investors of Newron Pharmaceuticals SpA, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of Newron Pharmaceuticals SpA?

Low debt means that Newron Pharmaceuticals SpA has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from Newron Pharmaceuticals SpA affect the company?

An increase in debt of Newron Pharmaceuticals SpA can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of Newron Pharmaceuticals SpA affect the company?

A reduction in debt of Newron Pharmaceuticals SpA can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of Newron Pharmaceuticals SpA?

Some factors that can influence the debt of Newron Pharmaceuticals SpA include investments, acquisitions, operating costs, and revenue development.

Why are the debts of Newron Pharmaceuticals SpA so important for investors?

The debts of Newron Pharmaceuticals SpA are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can Newron Pharmaceuticals SpA take to change the debt?

To change the debt, Newron Pharmaceuticals SpA can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does Newron Pharmaceuticals SpA pay?

Over the past 12 months, Newron Pharmaceuticals SpA paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Newron Pharmaceuticals SpA is expected to pay a dividend of 0 EUR.

What is the dividend yield of Newron Pharmaceuticals SpA?

The current dividend yield of Newron Pharmaceuticals SpA is .

When does Newron Pharmaceuticals SpA pay dividends?

Newron Pharmaceuticals SpA pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Newron Pharmaceuticals SpA?

Newron Pharmaceuticals SpA paid dividends every year for the past 0 years.

What is the dividend of Newron Pharmaceuticals SpA?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Newron Pharmaceuticals SpA located?

Newron Pharmaceuticals SpA is assigned to the 'Health' sector.

Wann musste ich die Aktien von Newron Pharmaceuticals SpA kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Newron Pharmaceuticals SpA from 1/4/2025 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 1/4/2025.

When did Newron Pharmaceuticals SpA pay the last dividend?

The last dividend was paid out on 1/4/2025.

What was the dividend of Newron Pharmaceuticals SpA in the year 2024?

In the year 2024, Newron Pharmaceuticals SpA distributed 0 EUR as dividends.

In which currency does Newron Pharmaceuticals SpA pay out the dividend?

The dividends of Newron Pharmaceuticals SpA are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Newron Pharmaceuticals SpA

Our stock analysis for Newron Pharmaceuticals SpA Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Newron Pharmaceuticals SpA Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.